Editor’s Special Episode: Treating CLL Now and in the Future

In an Editor’s Special Epsidoe of the HemOnc Pulse, Alexey Danilov, MD, PhD, joins us for an in-depth discussion on some of the most pressing challenges and promising advancements in chronic lymphocytic leukemia (CLL) treatment. Dr. Danilov explores key unmet medical needs in CLL, including managing immune deficiency, minimizing therapy without sacrificing efficacy, and addressing the complexities of Richter’s transformation. He also reflects on the limitations of current therapies like anti-CD20 antibodies and CAR T cells in preserving immune function. As the conversation wraps up, Dr. Danilov highlights exciting new data presented at recent congresses on BTK degraders in double-refractory CLL, including agents showing strong response rates and excellent tolerability. This episode is a must-listen for anyone interested in the evolving CLL treatment landscape and what’s on the horizon for patients with limited options.